Skip to main content
SpringerLink
Log in

Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination

  • Review Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Herpes zoster (HZ) results from reactivation of varicella zoster virus which has been persistent but clinically latent in dorsal root and cranial nerve ganglia since primary infection, usually as a child, with varicella (chicken pox). HZ affects 20–30% of individuals during their lifetime and up to 50% of those ≥80 years old. Although serious life- or sight-threatening complications occur rarely, postherpetic neuralgia (PHN) is the most common complication. Both HZ and PHN are most common in the elderly. Declining cell-mediated immunity resulting from immune senescence appears to be the cause. Incidence of HZ is also high in individuals who are immunocom-promised as a result of disease or its treatment. HZ also occurs in younger and fit individuals but is usually mild and complications are rare.

Current management of HZ with antiviral drugs and analgesics attains quite good control of acute pain and skin rash but offers only partial protection against PHN. Other strategies studied to prevent PHN such as nerve blocks are relatively ineffective and clinically impractical. Although several drug classes are used to manage PHN, numbers needed to treat to obtain 50% pain reduction range from approx. 2.5-5 and adverse effects are common.

The elderly population is growing and thus the number of HZ and PHN susceptible individuals is increasing. HZ and PHN are expensive in terms of suffering, loss of independence and healthcare costs. Significant numbers of the elderly with HZ require hospitalization. Short-term illness in the elderly can lead to long-term loss of independence.

A live attenuated herpes zoster vaccine has been studied in a large number of subjects and shown to reduce incidence of HZ as well as incidence and severity of PHN. The safety profile of the vaccine is good, local soreness at the injection site being the only common adverse event. Health economics studies suggest that vaccination of adults about 60 years of age would be cost effective. Duration of protection following vaccination is the subject of ongoing surveillance, as is the potential benefit of vaccinating younger and sicker members of the population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. de Melker H, Berbers G, Hahne S et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24: 3946–52.

    Article  PubMed  Google Scholar 

  2. Kilgore PE, Kruszon-Moran D, Seward JF et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70 (Suppl 1): S111–8.

    Article  PubMed  Google Scholar 

  3. Yawn BP, Saddier P, Wallen PC, St Sauvier JL, Kurland MJ. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341–9.

    Article  PubMed  Google Scholar 

  4. Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305–14.

    Article  PubMed  CAS  Google Scholar 

  5. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975: 25: 571–5.

    PubMed  CAS  Google Scholar 

  6. Helgason S, Sigurdsson J, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12–5.

    Article  Google Scholar 

  7. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38–47.

    Article  PubMed  CAS  Google Scholar 

  8. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19: 471–5.

    Article  PubMed  Google Scholar 

  9. Hurley LP, Harpaz R, Daley MF et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis 2008; 197 (Suppl 2): S216–23.

    Article  PubMed  Google Scholar 

  10. Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002; 44: 211–9.

    Article  PubMed  CAS  Google Scholar 

  11. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545–51.

    Article  PubMed  Google Scholar 

  12. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–84.

    Article  PubMed  CAS  Google Scholar 

  13. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18: 350–4.

    Article  PubMed  Google Scholar 

  14. Coplan PM, Schmader K, Nikas A et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5: 344–56.

    Article  PubMed  Google Scholar 

  15. Schmader KE, Sloane R, Pieper C et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23: 490–6.

    Article  PubMed  Google Scholar 

  16. Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25: 991–1006.

    Article  PubMed  CAS  Google Scholar 

  17. Oaklander AL, Bowsher D, Galer B, Haanpaa M, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003; 4: 338–43.

    Article  PubMed  Google Scholar 

  18. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27: 1454–67.

    Article  PubMed  Google Scholar 

  19. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006; 24: 1308–14.

    Article  PubMed  Google Scholar 

  20. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25: 8326–37.

    Article  PubMed  Google Scholar 

  21. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27: 520–9.

    Article  PubMed  Google Scholar 

  22. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266–7.

    Article  PubMed  CAS  Google Scholar 

  23. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310–6.

    CAS  Google Scholar 

  24. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605–9.

    Article  PubMed  CAS  Google Scholar 

  25. Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999; 3: 335–42.

    Article  PubMed  Google Scholar 

  26. Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl 1): 1–26.

    Article  Google Scholar 

  27. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: 628–44.

    Article  CAS  Google Scholar 

  28. Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008; 9 ( Suppl 1): S19–30.

    PubMed  CAS  Google Scholar 

  29. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305.

    Article  PubMed  CAS  Google Scholar 

  30. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63: 959–65.

    Article  PubMed  CAS  Google Scholar 

  31. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999: 80: 533–8.

    Article  PubMed  CAS  Google Scholar 

  32. Meier T, Wasner G, Faust M et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151–8.

    Article  PubMed  CAS  Google Scholar 

  33. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65: 39–44.

    Article  PubMed  CAS  Google Scholar 

  34. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341–7.

    Article  PubMed  CAS  Google Scholar 

  35. Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19: 47–55.

    Article  Google Scholar 

  36. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255–64.

    PubMed  CAS  Google Scholar 

  37. Tyring S, Barbarash RA, Nahlik JE et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995; 123: 89–96.

    Article  PubMed  CAS  Google Scholar 

  38. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546–53.

    Article  PubMed  CAS  Google Scholar 

  39. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896–900.

    Article  PubMed  CAS  Google Scholar 

  40. Whitley RJ, Weiss H, Gnann JW Jr. et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125: 376–83.

    CAS  Google Scholar 

  41. van Wijck AJ, Opstelten W, Moons KG et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006; 367: 219–24.

    Article  PubMed  Google Scholar 

  42. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87: 121–9.

    Article  PubMed  CAS  Google Scholar 

  43. Pasqualucci A, Pasqualucci V, Galla F et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol Scand 2000; 44: 910–8.

    Article  PubMed  CAS  Google Scholar 

  44. Manabe H, Dan K, Hirata K et al. Optimum pain relief with continuous epidural infusion of local anesthetics shortens the duration of zoster-associated pain. Clin J Pain 2004; 20: 302–8.

    Article  PubMed  Google Scholar 

  45. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327–31.

    Article  PubMed  CAS  Google Scholar 

  46. Tenser RB, Dworkin RH. Herpes zoster and the prevention of postherpetic neuralgia: beyond antiviral therapy. Neurology, 2005; 65: 349–50.

    Article  PubMed  Google Scholar 

  47. Schmader K, Oxman MN, Levin M et al. persistence of zoster vaccine efficacy. In ICAAC/IDSA. Washington DC, USA, 2008.

  48. Paek E, Johnson RW. Public awareness and knowledge of herpes zoster: results of a global survey. Gerontology 2009 (in press)

  49. Johnson R. Patient awareness of herpes zoster: the global herpes zoster survey — a preliminary report. Herpes 2006; 13 (Suppl 1): 40–41.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Bristol, Bristol, UK

    Robert W. Johnson MD

Authors
  1. Robert W. Johnson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert W. Johnson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, R.W. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Aging Clin Exp Res 21, 236–243 (2009). https://doi.org/10.1007/BF03324909

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324909

Keywords

Search

Navigation